The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is a huge mover today! The stock decreased 3.96% or $0.55 during the last trading session, hitting $13.35. About 656,845 shares traded hands or 22.57% up from the average. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 42.13% since April 13, 2016 and is uptrending. It has outperformed by 38.20% the S&P500.
The move comes after 8 months negative chart setup for the $965.50M company. It was reported on Nov, 15 by Barchart.com. We have $12.55 PT which if reached, will make NASDAQ:MNTA worth $57.93M less.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Ratings Coverage
Out of 8 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 1 “Hold”. This means 63% are positive. Momenta Pharmaceuticals has been the topic of 16 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Tuesday, October 11, the company rating was upgraded by Barclays Capital. On Friday, November 13 the stock rating was initiated by JP Morgan with “Overweight”. Maxim Group upgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Friday, January 8 to “Hold” rating. The rating was downgraded by Goldman Sachs on Thursday, August 6 to “Neutral”. The stock has “Neutral” rating given by Goldman Sachs on Monday, June 6. Maxim Group downgraded the stock to “Sell” rating in Wednesday, September 7 report. The stock has “Equal-Weight” rating given by Barclays Capital on Monday, November 23. Leerink Swann maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Wednesday, May 4. Leerink Swann has “Outperform” rating and $18 price target. On Tuesday, October 13 the stock rating was maintained by Leerink Swann with “Outperform”.
According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”
Insitutional Activity: The institutional sentiment increased to 1.38 in Q2 2016. Its up 0.21, from 1.17 in 2016Q1. The ratio improved, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
California Employees Retirement Sys last reported 152,900 shares in the company. California State Teachers Retirement Sys owns 136,276 shares or 0% of their US portfolio. Blackrock Advsrs Ltd Limited Liability Company holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 90,261 shares. Price T Rowe Associates Md reported 951,864 shares or 0% of all its holdings. Morgan Stanley owns 62,566 shares or 0% of their US portfolio. Ny State Common Retirement Fund accumulated 256,437 shares or 0% of the stock. Moreover, Wells Fargo & Mn has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 173,185 shares. Dekabank Deutsche Girozentrale last reported 38,900 shares in the company. Moreover, Vanguard Gp has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 4.75 million shares. Capstone Asset Communications holds 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 18,183 shares. State Board Of Administration Of Florida Retirement Sys last reported 53,502 shares in the company. Swiss Fincl Bank last reported 113,700 shares in the company. Texas Permanent School Fund reported 48,356 shares or 0.01% of all its holdings. Northern Trust Corp last reported 0% of its portfolio in the stock. Moreover, Louisiana State Employees Retirement System has 0.02% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 28,000 shares.
Insider Transactions: Since May 19, 2016, the stock had 0 insider buys, and 6 selling transactions for $188,231 net activity. On Thursday, May 19 the insider Roach James M. sold $11,116. Bishop John E also sold $7,997 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares. Shares for $10,690 were sold by Kaundinya Ganesh Venkataraman on Thursday, May 19. Another trade for 1,030 shares valued at $12,415 was sold by Leicher Bruce. Shares for $70,704 were sold by WHEELER CRAIG A on Friday, August 19. Another trade for 972 shares valued at $11,717 was sold by Shea Richard P. 5,200 shares were sold by Shapiro Bennett M, worth $67,600.
More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales” on November 04, 2016, also Fool.com with their article: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” published on October 11, 2016, Fool.com published: “Why Momenta Pharmaceuticals, Inc. Was Up Today” on January 08, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” published on March 04, 2016 as well as Fool.com‘s news article titled: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” with publication date: August 09, 2016.
MNTA Company Profile
Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.